High-resolution structures of Trypanosoma brucei pteridine reductase ligand complexes inform on the placement of new molecular entities in the active site of a potential drug target.
Dawson, A., Tulloch, L.B., Barrack, K.L., Hunter, W.N.(2010) Acta Crystallogr D Biol Crystallogr 66: 1334-1340
- PubMed: 21123874 
- DOI: https://doi.org/10.1107/S0907444910040886
- Primary Citation of Related Structures:  
2X9G, 2X9N, 2X9V, 3MCV - PubMed Abstract: 
Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species. These protozoa cause serious diseases for which current therapies are inadequate. High-resolution structures have been determined, using data between 1.6 and 1.1 Å resolution, of T. brucei PTR1 in complex with pemetrexed, trimetrexate, cyromazine and a 2,4-diaminopyrimidine derivative. The structures provide insight into the interactions formed by new molecular entities in the enzyme active site with ligands that represent lead compounds for structure-based inhibitor development and to support early-stage drug discovery.
Organizational Affiliation: 
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD15EH, Scotland.